Peptide therapy is one of the most consequential — and most confusing — topics in clinical practice in 2026. This guide gives providers one evidence-grounded map of the whole category: what peptides are, where the science is strong, and where the compliance lines sit.
The Foundation
Peptides are short chains of amino acids, typically 2 to 50 residues, joined by covalent peptide bonds through condensation. Chains of 10 to 20 residues are often called oligopeptides, and those above 20 polypeptides. What matters clinically is that peptides act as biologic signaling molecules: many of the hormones providers already prescribe or measure are peptides, including insulin, glucagon, growth hormone-releasing hormone (GHRH), oxytocin, and glucagon-like peptide-1 (GLP-1). Because peptides bind specific receptors, their effects tend to be targeted rather than broad.
The single most useful frame for the whole category is regulatory. Peptide therapies divide into three groups — FDA-approved, compounded, and investigational or unapproved — and that distinction carries direct prescribing, informed-consent, and liability implications. FDA-approved peptides include insulin analogs, semaglutide and tirzepatide (for type 2 diabetes and obesity), tesamorelin (for HIV-associated lipodystrophy), and bremelanotide (for hypoactive sexual desire disorder). Compounded peptides are prepared by pharmacies but are not FDA-approved. Investigational peptides have no approval and, in several cases, unresolved safety questions.
Three Regulatory Categories of Peptide Therapy
| Category | Examples | FDA Status | Prescribing Implications |
|---|---|---|---|
| FDA-Approved | Semaglutide, tirzepatide, insulin analogs, tesamorelin, bremelanotide | Approved | Standard prescribing; safety & efficacy verified by FDA |
| Compounded | Sermorelin, ipamorelin, CJC-1295 (503A/503B pharmacy) | Not Approved | Consent must state not FDA-approved; sourcing (503A vs 503B) determines permissibility |
| Investigational / Unapproved | BPC-157, TB-500, MOTS-c, Semax, Epitalon | Unapproved / Cat. 2 | No FDA approval; significant safety risks identified; PCAC review July 2026 |
Getting this category discipline right is the foundation for everything that follows. See our guide to FDA-approved peptides in 2026 and our full BPC-157 guide for providers.
Regulatory Landscape
The FDA is explicit that compounded drugs are not FDA-approved, and that the agency does not verify their safety, effectiveness, or quality before they are marketed. That statement anchors how providers should present compounded peptides to patients. Sourcing adds another layer: 503A pharmacies prepare patient-specific compounded prescriptions and cannot mass-produce, while 503B outsourcing facilities are FDA-registered and operate under current good manufacturing practice (cGMP), but are limited by the 503B bulks list.
Two developments define the 2026 picture. First, the compounded GLP-1 window has closed: the FDA determined the tirzepatide shortage resolved on December 19, 2024, and the semaglutide shortage on February 21, 2025, and the associated enforcement-discretion periods ended during 2025. Second, the Pharmacy Compounding Advisory Committee is scheduled to meet July 23–24, 2026 to discuss BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, and Epitalon for the 503A bulks list (docket FDA-2025-N-6895).
FDA Status Snapshot — Key Peptides (2026)
| Peptide | Status | Key Notes |
|---|---|---|
| Semaglutide | FDA-Approved | Shortage resolved Feb 21, 2025; compounded versions no longer permitted under shortage-based enforcement discretion |
| Tirzepatide | FDA-Approved | Shortage resolved Dec 19, 2024; same compounding restrictions apply |
| Tesamorelin | FDA-Approved | Approved for HIV-associated lipodystrophy |
| Sermorelin / Ipamorelin / CJC-1295 | Compounded | 503A/503B sourcing required; not FDA-approved; consent must reflect this |
| BPC-157 | Category 2 | Significant safety risks identified by FDA; PCAC review July 23–24, 2026 |
| TB-500, MOTS-c, KPV, Semax, Epitalon | PCAC-Pending | Under PCAC review July 23–24, 2026 (docket FDA-2025-N-6895) |
This is a moving target. Our FDA-approved peptides tracker keeps the current status in one place.
The Question Every Provider Gets
BPC-157 is a synthetic pentadecapeptide that patients frequently describe as a healing or recovery compound. The evidence does not yet support that reputation. Current data are largely drawn from animal studies, laboratory work, and case reports, with no large human randomized controlled trials. The FDA classifies BPC-157 as Category 2, meaning it has identified significant safety risks. Those two facts — thin human evidence and an active safety concern — are what a provider needs to convey plainly, especially with the July 2026 PCAC review pending.
⚠ FDA Category 2 — Significant Safety Risks Identified
BPC-157 has no large human RCTs. The Pharmacy Compounding Advisory Committee is scheduled to review it on July 23–24, 2026. Providers should verify current status before prescribing and ensure informed consent reflects the absence of FDA approval.
Discussing BPC-157 responsibly means separating what patients have heard from what the literature actually shows. Our full BPC-157 guide for providers walks through the evidence, the Category 2 status, and how to have the conversation.
Weight Management
The GLP-1 trials set the benchmark that every other weight-loss approach is measured against. In STEP 1, once-weekly semaglutide 2.4 mg produced a mean weight change of −14.9% versus −2.4% for placebo at 68 weeks. In SURMOUNT-1, tirzepatide 15 mg produced a mean weight change of −20.9% versus −3.1% for placebo at 72 weeks. Those are the numbers patients have read about, and they explain the demand providers are now managing.
Mean weight change vs. −2.4% placebo
STEP 1 — 68 weeks
Mean weight change vs. −3.1% placebo
SURMOUNT-1 — 72 weeks
With compounded GLP-1s no longer available under shortage-based enforcement discretion, providers need a compliant pathway to keep serving weight-management patients — one built on approved products and sound documentation rather than on compounding that no longer qualifies.
Legal Prescribing
Two principles carry most of the weight in prescribing peptides responsibly. The first: compounded does not mean approved. A compounded peptide has not been reviewed by the FDA for safety, effectiveness, or quality, and informed consent should reflect that. The second: sourcing determines what is permissible. Knowing whether a preparation comes from a 503A pharmacy (patient-specific, no mass production) or a 503B outsourcing facility (FDA-registered, cGMP, limited by the bulks list) is part of prescribing defensibly, not an administrative afterthought.
503A Pharmacy
Patient-specific prescriptions only. Cannot mass-produce. State-licensed. Not FDA-registered.
503B Outsourcing Facility
FDA-registered. Operates under cGMP. Can produce larger quantities but limited to the 503B bulks list.
Getting consent, sourcing, and documentation right is where legal exposure is won or lost. Our guide to prescribing peptides legally covers the workflow step by step.
GH Peptides
Growth hormone secretagogues stimulate the body’s own GH release through physiologic signaling rather than delivering exogenous growth hormone — a distinction that shapes both the clinical rationale and the risk profile. Monitoring follows from that same logic: insulin-like growth factor-1 (IGF-1) should be maintained within the age- and sex-appropriate reference range, not pushed as high as possible. Supraphysiologic IGF-1 is associated with increased cancer risk in epidemiologic data, so the goal is restoration, not maximization.
⚠ Clinical Monitoring Principle
Keep IGF-1 within the age- and sex-appropriate reference range. The goal is restoration, not maximization. Supraphysiologic IGF-1 is associated with increased cancer risk in epidemiologic data.
GHRH analog. Shorter half-life. Stimulates pulsatile GH release. Widely used; well-established compounding history.
GHRP. Highly selective for GH release with minimal effect on cortisol or prolactin. Often combined with CJC-1295.
Long-acting GHRH analog. Extended half-life due to DAC modification. Typically paired with ipamorelin for sustained GH pulse.
Sermorelin, ipamorelin, and CJC-1295 differ meaningfully in half-life, selectivity, and practical use. Our side-by-side comparison breaks down how to choose among them.
Training & Certification
Peptide therapy sits at the intersection of aesthetic, regenerative, and weight-management medicine, and most existing training assumes a functional-medicine baseline that many providers entering the field do not have. A rigorous certification should cover the full category — the science, the three regulatory tiers, sourcing, consent, monitoring, and the practice-side workflow — as a single, coherent entry path rather than a collection of product tutorials.
Genuine CME credit
All three regulatory tiers covered
Sourcing, consent & monitoring
Practice-side workflow included
Clear scope & clinical judgment focus
Not a collection of product tutorials
Choosing well matters because certification is the closest step to actually offering peptide therapy. Our guide to evaluating peptide therapy certification compares what programs include.
View the IAPAM Peptide Therapy Course →Practice Integration
The economics of peptide therapy favor a cash-pay or concierge model, which is currently the dominant structure. Initial consultations commonly run $200 to $500, with monthly program fees commonly $150 to $400. Those figures make a sustainable program realistic for many practices, but the model only holds if the marketing stays compliant.
Initial Consultation
$200–$500
Typical range
Monthly Program Fee
$150–$400
Typical range
Marketing Compliance Warning
Making disease treatment or cure claims about unapproved compounded peptides — for example, stating that BPC-157 heals tendons — risks FDA enforcement. The FTC separately requires that health claims be substantiated and that typical results be disclosed.
Building the offering and the messaging together, from the start, is far easier than retrofitting compliance later. Our guide to adding peptide therapy to your practice covers pricing, workflow, and compliant marketing in detail.
Key Takeaways & FAQ
Category discipline comes first
Every peptide falls into one of three regulatory tiers — FDA-approved, compounded, or investigational — and that placement drives prescribing, consent, and liability.
Compounded is not approved
The FDA does not verify the safety, effectiveness, or quality of compounded peptides before marketing. Consent should say so explicitly.
The evidence is uneven
GLP-1 weight-loss data are strong (−14.9% semaglutide, −20.9% tirzepatide). BPC-157 rests on animal and case-report data and is FDA Category 2.
Sourcing & marketing are compliance decisions
Know your 503A versus 503B sourcing, and keep claims substantiated to stay clear of FDA and FTC action.
Timing matters in 2026
The compounded GLP-1 window has closed. The PCAC reviews BPC-157 and related peptides on July 23–24, 2026.
GH peptides: restoration, not maximization
Keep IGF-1 within the age- and sex-appropriate range. Supraphysiologic IGF-1 carries increased cancer risk in epidemiologic data.
Peptide therapy uses short chains of amino acids (typically 2 to 50 residues) that act as biologic signaling molecules to influence specific physiologic processes, from metabolism to tissue signaling.
Some are. Peptide therapies fall into three categories: FDA-approved (such as insulin analogs, semaglutide, tirzepatide, tesamorelin, and bremelanotide), compounded, and investigational. Compounded peptides are not FDA-approved, and the agency does not verify their safety, effectiveness, or quality before marketing.
BPC-157 is currently classified by the FDA as Category 2, reflecting identified significant safety risks, and its human evidence is limited to animal studies, lab work, and case reports. The Pharmacy Compounding Advisory Committee is scheduled to review it on July 23–24, 2026, so its compounding status may change. Providers should verify the current status before prescribing.
The shortage-based basis for compounding has ended. The FDA determined the tirzepatide shortage resolved on December 19, 2024, and the semaglutide shortage on February 21, 2025, and the related enforcement-discretion periods ended in 2025. Providers should plan around approved products.
The GLP-1 peptides have strong trial evidence. Once-weekly semaglutide 2.4 mg produced a −14.9% mean weight change versus −2.4% for placebo at 68 weeks (STEP 1), and tirzepatide 15 mg produced −20.9% versus −3.1% at 72 weeks (SURMOUNT-1). Evidence for many other peptides marketed for weight loss is far weaker.
Most peptide programs run on a cash-pay or concierge model. Initial consultations commonly range from $200 to $500, with monthly program fees commonly between $150 and $400.
References
IAPAM Peptide Therapy Course
Reading the evidence, sourcing correctly, and staying compliant is exactly what the IAPAM peptide therapy course is designed to deliver — as a single, coherent entry path built for busy clinicians.